Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to ...

The FDA has rebuked Viatris for a direct-to-consumer (DTC) video that allegedly misled viewers about a cystic fibrosis ...

It was another swing and a miss for the biopharma industry on Thursday, when a federal appeals court in Philadelphia unanimously rejected (PDF) a challenge by Novartis on the legality of the Inflation ...

As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines ...

The U.K. pharma marketing watchdog has slammed AGB Pharma for misleadingly implying a lack of fertility considerations for ...

Consider it a new supercharged player in the AI marketing game.  | The Considered+AI is an AI-native agency that's been ...

The three-year initiative is designed to generate 1.9 billion pound sterling ($2.5 billion) in annual cost savings by 2029, against 2.4 billion pound sterling in total one-time costs.  The cost ...

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the ...

Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second ...

A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach ...

J&J has proposed a $5.5 billion settlement that could resolve roughly 76,000 multi-district litigation and state-level ...